Malignancies After Lung Transplantation

Overview

Journal Transpl Int

Specialty General Surgery

Date 2024 Sep 24

PMID 39314925

Authors

Caroline Stenman

Andreas Wallinder

Erik Holmberg

Kristjan Karason

Jesper Magnusson

Goran Dellgren

Affiliations

Soon will be listed here.

Abstract

Lung transplantation (LTx) is a well-known treatment for end-stage lung disease. This study aimed to report the incidence of cancer after LTx and long-term outcome among lung transplant recipients with a pretransplant diagnosis of cancer. Patients who underwent LTx between 1990-2016 were included in the study. Detection of cancer was obtained by cross-checking the study population with the Swedish Cancer Registry and the Cause-of-Death registry. A total of 614 patients were followed for a median of 5.1 years. In all, 159 malignancies were diagnosed. The excess risk of cancer or standardized incidence ratio (SIR) following LTx was 5.6-fold compared to the general Swedish population. The most common malignancies were non-melanoma skin cancer (NMSC) (SIR 76.5 (95%CI 61.7-94.8); non-Hodgkin lymphoma (SIR 23.5, 95%CI 14.8-37.2); and lung cancer (SIR 8.89, 95%CI 5.67-13.9). There was no significant difference in overall survival between those with and without a history of cancer before LTx (p = 0.56). In total, 159 malignancies were identified after LTx, which was a 5.6-fold higher relative to the general population. A history of previous cancer yields similar survival in selected recipients, compared to those without cancer prior to LTx.

References

Perez-Callejo D, Torrente M, Parejo C, Laporta R, Ussetti P, Provencio M . Lung cancer in lung transplantation: incidence and outcome. Postgrad Med J. 2017; 94(1107):15-19. DOI: 10.1136/postgradmedj-2017-134868. View

Euvrard S, Kanitakis J, Pouteil-Noble C, Disant F, Dureau G, Finaz de Villaine J . Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc. 1995; 27(2):1767-8. View

Barlow L, Westergren K, Holmberg L, Talback M . The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2008; 48(1):27-33. DOI: 10.1080/02841860802247664. View

Gilljam M, Nystrom U, Dellgren G, Skog I, Hansson L . Survival after lung transplantation for cystic fibrosis in Sweden. Eur J Cardiothorac Surg. 2017; 51(3):571-576. DOI: 10.1093/ejcts/ezw328. View

. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev. 2005; 14(4):307-8. DOI: 10.1097/00008469-200508000-00002. View

van den Hoogen M, Hoitsma A, Hilbrands L . Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. Expert Opin Biol Ther. 2012; 12(8):1031-42. DOI: 10.1517/14712598.2012.689278. View

Penn I, HAMMOND W, BRETTSCHNEIDER L, Starzl T . Malignant lymphomas in transplantation patients. Transplant Proc. 1969; 1(1):106-12. PMC: 2845467. View

Zaffiri L, Long A, Neely M, Cherikh W, Chambers D, Snyder L . Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry. J Heart Lung Transplant. 2020; 39(10):1089-1099. PMC: 7530100. DOI: 10.1016/j.healun.2020.06.010. View

Yusen R, Edwards L, Kucheryavaya A, Benden C, Dipchand A, Goldfarb S . The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015; 34(10):1264-77. DOI: 10.1016/j.healun.2015.08.014. View

10.

Engels E, Pfeiffer R, Fraumeni Jr J, Kasiske B, Israni A, Snyder J . Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306(17):1891-901. PMC: 3310893. DOI: 10.1001/jama.2011.1592. View

11.

Berastegui C, Laporta R, Lopez-Meseguer M, Romero L, Gomez-Olles S, Riera J . Epidemiology and Risk Factors for Cancer After Lung Transplantation. Transplant Proc. 2017; 49(10):2285-2291. DOI: 10.1016/j.transproceed.2017.09.043. View

12.

Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B . Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003; 89(7):1221-7. PMC: 2394311. DOI: 10.1038/sj.bjc.6601219. View

13.

Scheffner I, Gietzelt M, Abeling T, Marschollek M, Gwinner W . Patient Survival After Kidney Transplantation: Important Role of Graft-sustaining Factors as Determined by Predictive Modeling Using Random Survival Forest Analysis. Transplantation. 2019; 104(5):1095-1107. DOI: 10.1097/TP.0000000000002922. View

14.

Chatron E, Degot T, Salvaterra E, Dumazet A, Porzio M, Hirschi S . Lung cancer after lung transplantation: An analysis of 25 years of experience in a single institution. Clin Transplant. 2018; 33(1):e13446. DOI: 10.1111/ctr.13446. View

15.

Collett D, Mumford L, Banner N, Neuberger J, Watson C . Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010; 10(8):1889-96. DOI: 10.1111/j.1600-6143.2010.03181.x. View

16.

Ippoliti G, Rinaldi M, Pellegrini C, Vigano M . Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol. 2005; 56(1):101-13. DOI: 10.1016/j.critrevonc.2005.03.013. View

17.

Hall E, Pfeiffer R, Segev D, Engels E . Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013; 119(12):2300-8. PMC: 4241498. DOI: 10.1002/cncr.28043. View

18.

Brown S, Dobelle M, Padilla M, Agovino M, Wisnivesky J, Hashim D . Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis. Ann Am Thorac Soc. 2019; 16(8):1041-1051. DOI: 10.1513/AnnalsATS.201807-481OC. View

19.

Dickson R, Davis R, Rea J, Palmer S . High frequency of bronchogenic carcinoma after single-lung transplantation. J Heart Lung Transplant. 2006; 25(11):1297-301. PMC: 3693444. DOI: 10.1016/j.healun.2006.09.009. View

20.

Triplette M, Crothers K, Mahale P, Yanik E, Valapour M, Lynch C . Risk of lung cancer in lung transplant recipients in the United States. Am J Transplant. 2018; 19(5):1478-1490. PMC: 6872188. DOI: 10.1111/ajt.15181. View